Hosted on MSN2d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...
Business Wire3d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
The agreement combines Dr. Reddy’s global commercial presence with Henlius’ proven capabilities in developing biosimilars for markets worldwide. Under the terms of the agreement, Henlius will ...
Dr Reddy's in pact with Shanghai Henlius Biotech for exclusive US, Europe rights for daratumumab biosimilar
HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...
Hosted on MSN7d
Shanghai Henlius Biotech’s HLX11 BLA Accepted by FDA
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech, Inc. announced that its ...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, ...
Daily2d
Dr Reddy's Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, Europe
Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...